Literature DB >> 8682029

Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Implications for possible antiarrhythmic and proarrhythmic mechanisms.

D Katritsis1, E Rowland, S O'Nunain, C F Shakespeare, J Poloniecki, A J Camm.   

Abstract

We studied the effects of intravenous flecainide (2 mg.kg-1) on atrial and ventricular refractoriness and conduction during sinus rhythm, induced atrial fibrillation and atrial pacing at rates of 100, 120 and 150 ppm, in 14 patients with normal left ventricle. Flecainide caused a significant increase in QRS duration during sinus rhythm (mean +/- SD: 87.2 +/- 8.4 ms vs 102.8 +/- 9.1 ms, P < 0.001), atrial fibrillation (87.8 +/- 10.0 ms vs 108.8 +/- 13.7 ms, P < 0.001) and at all paced rates. The duration of the atrial electrogram was significantly increased during sinus rhythm (54.9 +/- 13.2 ms vs 64.8 +/- 16.6 ms, P = 0.003) and at all pacing rates. The PA interval was also significantly prolonged, as was the pacing stimulus-to-atrial-electrogram interval at all pacing rates. There was increased QRS duration and atrial electrogram prolongation at higher pacing rates. Atrial refractoriness was prolonged during sinus rhythm (216.4 +/- 28.2 vs 228.6 +/- 36.1, P = 0.02), but not during atrial pacing at any rate. The QT interval, but not the JT interval or ventricular refractoriness, was significantly prolonged during sinus rhythm and at all pacing rates. Flecainide slows atrial conduction in a use dependent manner and increases atrial refractoriness during sinus rhythm but not during faster atrial pacing, thus not displaying a use-dependent effect. QRS duration is prolonged in a use-dependent manner without a commensurate increase in ventricular refractoriness. In the presence of rapidly conducted atrial fibrillation, which was not found to be slowed by flecainide, this effect may constitute a proarrhythmic mechanism even in patients with no apparent myocardial abnormality.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8682029     DOI: 10.1093/oxfordjournals.eurheartj.a060850

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  7 in total

1.  Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Christian van der Werf; Prince J Kannankeril; Frederic Sacher; Andrew D Krahn; Sami Viskin; Antoine Leenhardt; Wataru Shimizu; Naokata Sumitomo; Frank A Fish; Zahurul A Bhuiyan; Albert R Willems; Maurits J van der Veen; Hiroshi Watanabe; Julien Laborderie; Michel Haïssaguerre; Björn C Knollmann; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

2.  Flecainide increases Kir2.1 currents by interacting with cysteine 311, decreasing the polyamine-induced rectification.

Authors:  Ricardo Caballero; Pablo Dolz-Gaitón; Ricardo Gómez; Irene Amorós; Adriana Barana; Marta González de la Fuente; Lourdes Osuna; Juan Duarte; Angelica López-Izquierdo; Ignacio Moraleda; Enrique Gálvez; José Antonio Sánchez-Chapula; Juan Tamargo; Eva Delpón
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

3.  High-resolution analysis of the surface P wave as a measure of atrial electrophysiological substrate.

Authors:  Damian P Redfearn; Joanne Lane; Kevin Ward; Peter J Stafford
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-01       Impact factor: 1.468

4.  Gene mutations in cardiac arrhythmias: a review of recent evidence in ion channelopathies.

Authors:  Pi-Yin Hsiao; Hui-Chun Tien; Chu-Pin Lo; Jyh-Ming Jimmy Juang; Yi-Hsin Wang; Ruey J Sung
Journal:  Appl Clin Genet       Date:  2013-01-18

5.  Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts.

Authors:  S C Salvage; J H King; K H Chandrasekharan; D I G Jafferji; L Guzadhur; H R Matthews; C L-H Huang; J A Fraser
Journal:  Acta Physiol (Oxf)       Date:  2015-04-23       Impact factor: 6.311

6.  An infrared optical pacing system for screening cardiac electrophysiology in human cardiomyocytes.

Authors:  Matthew T McPheeters; Yves T Wang; Andreas A Werdich; Michael W Jenkins; Kenneth R Laurita
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

Review 7.  Towards the Development of AgoKirs: New Pharmacological Activators to Study Kir2.x Channel and Target Cardiac Disease.

Authors:  Laura van der Schoor; Emma J van Hattum; Sophie M de Wilde; Netanja I Harlianto; Aart-Jan van Weert; Meye Bloothooft; Marcel A G van der Heyden
Journal:  Int J Mol Sci       Date:  2020-08-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.